2 active not recruiting, 1 completed, 1 withdrawn. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Completed 1 |
Follow AgeneBio: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults AGB101, Placebo - Hippocampal Overactivity, Dementia | Phase 2 | Active not recruiting | Johns Hopkins University | 60 | 2025-04-17 | 2026-08-31 |
| Clinical Trial of AGB101 for Mild Cognitive Impairment AGB101, Placebo - Mild Cognitive Impairment, Prodromal Alzheimer's Disease | Phase 2 | Withdrawn | AgeneBio | 2024-12-03 | 2025-05-25 | |
| Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis AGB101 - Parkinson Disease Psychosis | Phase 2 | Active not recruiting | Johns Hopkins University | 30 | 2023-09-28 | 2026-10-07 |
| Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease Placebo Oral Tablet, AGB101 220 mg tablet - Mild Cognitive Impairment, Prodromal Alzheimer's Disease | Phase 2 / Phase 3 | Completed | AgeneBio | 164 | 2018-12-13 | 2024-05-17 |
Cognitive Dysfunction (2) · Dementia (1)
Levetiracetam (3) · Sugars (1) · Tablets (1)
United States (4) · Canada (1)
Arnold Bakker, Ph.D. (2) · Marilyn Albert, PhD (1) · Richard Mohs, PhD (1) · Russell Barton, MS (1) · Sharon Rosenzweig-Lipson, PhD (1)
R01AG061091 (2), R01AG048349 (1), R56AG055416 (1)